← Back to Search

Other

Reproxalap Ophthalmic Solution (0.25%) for Dry Eye Syndrome

Phase 2
Waitlist Available
Research Sponsored by Aldeyra Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up on the first day of two consecutive dosing days for both crossover periods
Awards & highlights

Study Summary

This trial will compare the efficacy and safety of a new eye drop, Reproxalap, to a placebo drop in people with dry eye disease.

Eligible Conditions
  • Dry Eye Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~on the second day of two consecutive dosing days for both crossover periods
This trial's timeline: 3 weeks for screening, Varies for treatment, and on the second day of two consecutive dosing days for both crossover periods for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline in conjunctival redness in a dry eye chamber
Schirmer's test mean change from baseline
Secondary outcome measures
Schirmer's test ≥10mm responder analysis of change from baseline

Side effects data

From 2021 Phase 2 trial • 158 Patients • NCT04971031
4%
General disorders and administration site conditions
100%
80%
60%
40%
20%
0%
Study treatment Arm
Vehicle
Reproxalap (0.25%)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Reproxalap Ophthalmic Solution (0.25%)Experimental Treatment1 Intervention
Group II: Vehicle Ophthalmic SolutionPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Reproxalap Ophthalmic Solution (0.25%)
2022
Completed Phase 3
~2690

Find a Location

Who is running the clinical trial?

Aldeyra Therapeutics, Inc.Lead Sponsor
29 Previous Clinical Trials
3,970 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease
2022. "A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05424549.
~20 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top